References
Fautrel B, Sibilia J, Mariette X, Combe B (2004) Tumor necrosis factor (alpha) blocking agents in refractory adult Still’s disease: an observational study of 20 cases. Ann Rheum Dis 64:262–266
Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME (2002) Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 46:1171–1176
Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, Prost A (1995) Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54:587–590
Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA (1987) Adult-onset Still’s disease. Clinical course and outcome. Arthritis Rheum 30:186–194
Uppal SS, Pande IR, Kumar A, Kailash S, Sekharan NG, Adya CM, Malaviya AN (1995) Adult-onset Still’s disease in northern India: comparison with juvenile onset Still’s disease. Br J Rheumatol 34:429–434
Caramaschi P, Biasi D, Carletto A, Bambara LM (2002) A case of adult-onset Still’s disease treated with infliximab. Clin Exp Rheumatol 20:113
Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C (2001) Infliximab in the treatment of adult Still’s disease refractory to conventional therapy. Clin Exp Rheumatol 19:329–332
Kokkinos A, Iliopoulos A, Greka P, Efthymiou A, Katsilambros N, Sfikakis PP (2004) Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23:45–49
Kraetsch HG, Antoni C, Kalden JR, Manger B (2001) Successful treatment of a small cohort of patients with adult-onset of Still’s disease with infliximab: first experiences. Ann Rheum Dis 60 [Suppl 3]:iii55–iii57
Olivieri I, de Stefano G, Padula A, La Gala A, de Stefano C (2003) Infliximab in a case of early adult-onset Still’s disease. Clin Rheumatol 22:369–370
Asherson RA, Pascoe L (2002) Adult-onset Still’s disease: response to Enbrel. Ann Rheum Dis 61:859–860
Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A (2002) Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf 25:173–197
Dechant C, Schauenberg P, Antoni CE, Kraetsch HG, Kalden JR, Manger B (2004) Longterm outcome of TNF blockade in adult-onset Still’s disease. Dtsch Med Wochenschr 129:1308–1312
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430
Hench PK (1989) Evaluation and differential diagnosis of fibromyalgia. Approach to diagnosis and management. Rheum Dis Clin North Am 15:19–29
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33:160–172
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kumari, R., Uppal, S.S. Prolonged remission in adult-onset Still’s disease with etanercept. Clin Rheumatol 25, 106–108 (2006). https://doi.org/10.1007/s10067-004-1064-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-004-1064-7